Microneedle patch detects fentanyl and releases naloxone in mice

A patch smaller than a penny sits at the center of a Virginia Tech team’s attempt to change what happens during a fentanyl overdose. Called the iNal patch, it can detect fentanyl beneath the skin and automatically release naloxone, potentially providing an emergency response even when no bystander is there to help.

The device uses an array of 121 microscopic needles that penetrate only far enough to reach fluid just beneath the skin. Inside, porous silica nanoparticles carry naloxone. Their openings are sealed by fentanyl-sensitive molecular gates; when fentanyl reaches the patch, the gates open and the medication moves into the body. Higher fentanyl concentrations trigger larger releases, while unopened pores preserve naloxone for another response.

That repeatability addresses a difficult feature of overdose treatment: fentanyl’s effects may last longer than naloxone’s. In laboratory tests, the patch responded within minutes and continued releasing medication for up to 24 hours. In mice, it responded through at least three separate fentanyl exposures, and treated animals showed substantially fewer opioid-induced symptoms than mice exposed to fentanyl without the patch.

And so what, concretely? The device is aimed at people who may overdose alone, as well as situations in which someone is unsure whether another opioid dose has already been taken. It is designed as a harm-reduction tool, not as a replacement for pain treatment or medical care. The chemistry could also be adapted to recognize other opioids or release other blocking drugs, according to Wujin Sun, the Virginia Tech assistant professor who led the team.

The technology remains at the laboratory and animal-testing stage. Researchers reported no significant signs of irritation or other harmful effects in their tests, but they still need to examine how consistently the patch works over time, across different skin types and in real-world conditions, as well as how accurately it responds to different opioids. Sun and Zhao have filed a patent application, and Sun is exploring steps toward a product that could eventually move beyond the laboratory.